Biomirex Inc. is a drug discovery company that is focused on the development of antibody-based therapeutics.

Scientific board

Dr. Michael R. Farzan
Professor, The Scripps Research Institute, Jupiter, Florida
Immunologist, Experts in GPCRs, drug target validation. Discovered principal receptors of HIV fusion (CCR5). Phage display antibody libraries, multi-spanning membrane receptors, GPCR structure functions, chemokine receptors, adeno-associated virus (AAV), antibody humanization, germalization, structure-activity studies, adenoviral delivery of antibodies.

Dr. Alexey Finkelstein
Professor, Institute of Protein Research, Russian Acad. Sciences.
Foreign Member of Howard Hughes Medical Institute. Pushchino, Russia
Expertise: Protein physics, theoretical investigations of protein folding and stability, molecular physics and biology, biochemistry, biocomputing & protein engineering. We have ongoing collaborations on antibody optimization/charactrization, alternative scaffolds, study of receptor-antibody interaction.

Dr. Andrew Freywald
Professor, Dept. of Pathology, University of Saskatchewan, Canada.
Area of expertise: cancer cell biology, signal transduction, apoptosis, xenograft models of human cancer, metastasis, anti-cancer immunity, breast cancer, early cancer detection. We have two ongoing therapeutic MAB development programs

Dr. Masanori Aikawa
Director, Center for Interdisciplinary Cardiovascular Sciences, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA
Expertise: pathogenesis of atherosclerosis and metabolic disorders, macrophage biology, and the pro-inflammatory role of dyslipidemia, exploration for new therapeutic targets for cadiometabolic diseases. Macrophage activation in atherosclerosis, obesity, insulin resistance, and fatty liver. Therapeutic antibodies for metabolic diseases diseases and obesity, cardiovascular diseases, heart remodeling, cholesterol lowering.
We have an ongoing MAB discovery collaboration. Planning a second program.

Dr. Michael Sherman
Professor, Boston University Medical School, Boston, MA
Expertise in molecular and cell biology, cell membrane receptors, mechanism and modulation of cell signaling, libraries, bioinformatics, new targets. The role of heat shock proteins in cancer aggressiveness and tumorigenesis. Modulation of signaling pathways in oncogenenis, cell proliferation and transformation. We have and ongoing collaboration on MAB discovery.

Dr. Eugene Permyakov
Director of the Institute Biologic Instrumentation, Head of the Lab of Protein Physico-Chemistry, Russian Academy of Sciences, Pushchino, Russia
Expertise in biophysical methods of protein structure/function studies, Ca-binding proteins, cell signaling and membrane receptors, RAGE-signaling pathways, alternative scaffolds. We have two ongoing collaborations on therapeutic antibody discovery in for cancer

Dr. Valery Zinchenko
Professor, Lab of Cell Signaling, Institute of Cell Biophysics, Russian Academy of Sciences, Pushchino, Russia
Cell signaling, mechanism of action of GPCRs and ion channels targeting therapeutics. Beta adrenergic receptors in norm and pathology. Ca-signaling. Ligand and voltage gated ion channels. A metabolic disease/obesity involved GPCR antibody program to be started soon.

Dr. Kirill Martemyanov
Associate Professor, The Scripps Research Institute, Jupiter, Florida, USA
Expertise in molecular mechanism of vision, GPCR signaling pathways, mechanism of action of Regulator of G protein Signaling (RGS) proteins, discovery, characterization of novel G protein regulators, delineation of protein-protein interactions, trafficking and degradation of signaling proteins in cell culture and behavioral characterization of genetic mouse models with altered components of G protein signaling machinery.